Vertex announces casgevy® reimbursement agreement for the treatment of sickle cell disease in england

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) announced today a reimbursement agreement with nhs england for eligible sickle cell disease (scd) patients to access the crispr/cas9 gene-edited therapy, casgevy® (exagamglogene autotemcel). the reimbursement agreement comes as the national institute for health and care excellence (nice) issues positive guidance recommending casgevy's use in the nhs. it means that eligible scd patients in england now have access to the therapy follo.
VRTX Ratings Summary
VRTX Quant Ranking